Mutational analysis of the insulin‑like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients

Gately,Kathy; Forde,Lydia; Gray,Stephen; Morris,Derek; Corvin,Aidan; Tewari,Prerna; O'byrne,Kenneth

doi:10.3892/mco.2015.580

Mutational analysis of the insulin‑like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients

Authors:
- Kathy Gately
- Lydia Forde
- Stephen Gray
- Derek Morris
- Aidan Corvin
- Prerna Tewari
- Kenneth O'byrne
View Affiliations

Affiliations: Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Republic of Ireland, Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, Trinity College Dublin, St. James's Hospital, Dublin, Republic of Ireland, Discipline of Biochemistry, National University of Ireland, Galway, Republic of Ireland, Molecular Pathology Research Group, Trinity College, Coombe Womens and Infants University Hospital, Dublin, Republic of Ireland
Published online on: June 11, 2015 https://doi.org/10.3892/mco.2015.580
Pages: 1073-1079

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The insulin‑like growth factor 1 receptor (IGF1R) pathway plays an important role in the pathogenesis of non‑small cell lung cancer (NSCLC) and also provides a mechanism of resistance to targeted therapies. IGF1R is therefore an ideal therapeutic target and several inhibitors have entered clinical trials. However, thus far the response to these inhibitors has been poor, highlighting the importance of predictive biomarkers to identify patient cohorts who will benefit from these targeted agents. It is well‑documented that mutations and/or deletions in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain predict sensitivity of NSCLC patients to EGFR TK inhibitors. Single‑nucleotide polymorphisms (SNPs) in the IGF pathway have been associated with disease, including breast and prostate cancer. The aim of the present study was to elucidate whether the IGF1R TK domain harbours SNPs, somatic mutations or deletions in NSCLC patients and correlates the mutation status to patient clinicopathological data and prognosis. Initially 100 NSCLC patients were screened for mutations/deletions in the IGF1R TK domain (exons 16‑21) by sequencing analysis. Following the identification of SNP rs2229765, a further 98 NSCLC patients and 866 healthy disease‑free control patients were genotyped using an SNP assay. The synonymous SNP (rs2229765) was the only aberrant base change identified in the IGF1R TK domain of 100 NSCLC patients initially analysed. SNP rs2229765 was detected in exon 16 and was found to have no significant association between IGF1R expression and survival. The GA genotype was identified in 53.5 and 49.4% of NSCLC patients and control individuals, respectively. No significant difference was found in the genotype (P=0.5487) or allele (P=0.9082) frequencies between the case and control group. The present findings indicate that in contrast to the EGFR TK domain, the IGF1R TK domain is not frequently mutated in NSCLC patients. The synonymous SNP (rs2229765) had no significant association between IGF1R expression and survival in the cohort of NSCLC patients.

View Figures

View References

1	Larsson O, Girnita A and Girnita L: Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 92:2097–2101. 2005. View Article : Google Scholar : PubMed/NCBI
2	Riedemann J and Macaulay VM: IGF1R signalling and its inhibition. Endocr Relat Cancer. 13:(Suppl 1). S33–S43. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, et al: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol. 21:562–567. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM and Chang YS: Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: Immunohistochemical analysis. Korean J Intern Med. 23:116–120. 2008. View Article : Google Scholar : PubMed/NCBI
5	Li R, Pourpak A and Morris SW: Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 52:4981–5004. 2009. View Article : Google Scholar : PubMed/NCBI
6	Rochester MA, Riedemann J, Hellawell GO, Brewster SF and Macaulay VM: Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 12:90–100. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, et al: High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One. 4:e72732009. View Article : Google Scholar : PubMed/NCBI
8	Vanamala J, Reddivari L, Radhakrishnan S and Tarver C: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer. 10:2382010. View Article : Google Scholar : PubMed/NCBI
9	Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF and Macaulay VM: Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2942–2950. 2002.PubMed/NCBI
10	Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev. 28:20–47. 2007. View Article : Google Scholar : PubMed/NCBI
11	Yamamoto T, Oshima T, Yoshihara K, Nishi T, Arai H, Inui K, Kaneko T, Nozawa A, Adachi H, Rino Y, et al: Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer. Exp Ther Med. 3:797–802. 2012.PubMed/NCBI
12	Nakagawa M, Uramoto H, Oka S, Chikaishi Y, Iwanami T, Shimokawa H, So T, Hanagiri T and Tanaka F: Clinical significance of IGF1R expression in non-small-cell lung cancer. Clin Lung Cancer. 13:136–142. 2012. View Article : Google Scholar : PubMed/NCBI
13	Zhao S, Qiu Z, He J, Li L and Li W: Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: A meta-analysis. Int J Clin Exp Pathol. 7:6694–6704. 2014.PubMed/NCBI
14	Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, et al: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 20:842–849. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F and O'Byrne KJ: High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer. 15:58–66. 2014. View Article : Google Scholar : PubMed/NCBI
16	Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ and Jassem J: Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 32:2059–2066. 2014. View Article : Google Scholar : PubMed/NCBI
17	Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
19	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
20	Gazdar AF, Shigematsu H, Herz J and Minna JD: Mutations and addiction to EGFR: The Achilles ‘heal’ of lung cancers? Trends Mol Med. 10:481–486. 2004. View Article : Google Scholar : PubMed/NCBI
21	Weinstein IB, Joe A and Felsher D: Oncogene addiction. Cancer Res. 68:3077–3080. 2008. View Article : Google Scholar : PubMed/NCBI
22	Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, et al: IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet. 15:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
23	Feik E, Baierl A, Hieger B, Führlinger G, Pentz A, Stättner S, Weiss W, Pulgram T, Leeb G, Mach K, et al: Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control. 21:91–97. 2010. View Article : Google Scholar : PubMed/NCBI
24	Verheus M, McKay JD, Kaaks R, Canzian F, Biessy C, Johansson M, Grobbee DE, Peeters PH and van Gils CH: Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density. Breast Cancer Res Treat. 112:109–122. 2008. View Article : Google Scholar : PubMed/NCBI
25	Lönn S, Rothman N, Shapiro WR, Fine HA, Selker RG, Black PM, Loeffler JS, Hutchinson AA and Inskip PD: Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol. 10:553–559. 2008. View Article : Google Scholar : PubMed/NCBI
26	de Alencar SA and Lopes JCD: A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene. J Biomed Biotechnol. 2010:7151392010. View Article : Google Scholar : PubMed/NCBI
27	MacDonald K, Porter GA, Guernsey DL, Zhao R and Casson AG: A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma. Cancer Epidemiol. 33:37–40. 2009. View Article : Google Scholar : PubMed/NCBI
28	Li HR, Chen YS, Shao H, Han LL and Zhang XE: Association between polymorphisms of insulin-like growth factor receptor gene and susceptibility to non-small-cell lung cancer in Fujian Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 29:300–305. 2012.(In Chinese). PubMed/NCBI
29	Chen Y, Shao H, Li H, Han L and Zhang X: Relationship of insulin-like growth factor receptor single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 15:65–71. 2012.(In Chinese). PubMed/NCBI
30	Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, et al: Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res. 16:5591–5602. 2010. View Article : Google Scholar : PubMed/NCBI
31	Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT and Zheng W: Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: A report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat. 104:309–319. 2007. View Article : Google Scholar : PubMed/NCBI
32	Reinmuth N, Kloos S, Warth A, Risch A, Muley T, Hoffmann H, Thomas M and Meister M: Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. Hum Pathol. 45:1162–1168. 2014. View Article : Google Scholar : PubMed/NCBI
33	Mountain CF: The international system for staging lung cancer. Semin Surg Oncol. 18:106–115. 2000. View Article : Google Scholar : PubMed/NCBI
34	Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF and Sklar P: International Schizophrenia Consortium: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 460:748–752. 2009.PubMed/NCBI
35	Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW, et al: Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One. 7:e333222012. View Article : Google Scholar : PubMed/NCBI
36	Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, et al: Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer. 118:3993–4003. 2012. View Article : Google Scholar : PubMed/NCBI
37	Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM and Kimchi-Sarfaty C: Silent (synonymous) SNPs: Should we care about them? Methods Mol Biol. 578:23–39. 2009. View Article : Google Scholar : PubMed/NCBI
38	Cheng J, Liu J, Li X, Peng J, Han S, Zhang R, Xu Y and Nie S: Insulin-like growth factor-1 receptor polymorphism and ischemic stroke: A case-control study in Chinese population. Acta Neurol Scand. 118:333–338. 2008.PubMed/NCBI
39	Bonafè M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri C, Mugianesi E, Centurelli M, Franceschi C and Paolisso G: Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: Cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab. 88:3299–3304. 2003. View Article : Google Scholar : PubMed/NCBI
40	Diorio C, Brisson J, Bérubé S and Pollak M: Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev. 17:880–888. 2008. View Article : Google Scholar : PubMed/NCBI
41	Rasmussen SK, Lautier C, Hansen L, Echwald SM, Hansen T, Ekstrøm CT, Urhammer SA, Borch-Johnsen K, Grigorescu F, Smith RJ, et al: Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus. J Clin Endocrinol Metab. 85:1606–1610. 2000. View Article : Google Scholar : PubMed/NCBI